Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tretazicar SCHEMBL29375352 | 1.00 | MAPT (1.00) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL13685668 | 0.88 | MAPT (0.78) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL5581335 | 0.88 | MAPT (0.78) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL5827945 | 0.88 | MAPT (0.78) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3492841 | 0.86 | MAPT (0.75) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL11120951 | 0.85 | MAPT (0.74) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3362694 | 0.84 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL446497 | 0.84 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL29391567 | 0.84 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 | |
| SCHEMBL3678573 | 0.84 | MAPT (0.72) | MAPTCYP3A4BLMPMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145990-A1 | TRANS-SPLICING RNA (TSRNA) | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-05-08 | — | — | US | claimed |
| US-20240075051-A1 | TRANS-SPLICING RNA (tsRNA) | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-03-07 | — | — | US | claimed |
| EP-4316477-A1 | METHODS FOR TREATING CARDIAC VALVE DISEASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230364222-A1 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | DEVACELL, INC. | 2023-11-16 | — | — | US | claimed |
| US-11723987-B2 | Double suicide gene vector systems for stem cells | UNIVERSITY OF MIAMI (US) | 2023-08-15 | — | — | US | claimed |
| US-11517583-B2 | Trans-splicing RNA (tsRNA) | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-12-06 | — | — | US | claimed |
| US-11517530-B2 | Therapeutic agents specifically delivered by exosomes for cancer treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-06 | — | — | US | claimed |
| US-20220333079-A1 | GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH GENE ENCODING NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | SLBiGen, Inc. (KR) | 2022-10-20 | — | — | US | claimed |
| CN-115151635-A | Gene-modified NK cell lines transduced with genes encoding novel chimeric antigen receptors and uses thereof | 斯比根公司 | 2022-10-04 | — | — | CN | claimed |
| EP-4032972-A1 | GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH GENE ENCODING NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Slbigen Inc. (KR) | 2022-07-27 | — | — | EP | claimed |
| CN-101389320-A | Using alpha-hydroxycarbonyl compounds as reducing agents | MORVUS TECHNOLOGY LTD (GB) | 2009-03-18 | — | — | CN | claimed |
| EP-1951213-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | Morvus Technology Ltd. (GB) | 2008-08-06 | — | — | EP | claimed |
| US-20070254852-A1 | IMPROVED NITROREDUCTASE ENZYMES | UNITED STATES DEPARTMENT OF ENERGY | 2007-11-01 | — | — | US | claimed |
| WO-2007074344-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LIMITED (GB) | 2007-07-05 | — | — | WO | claimed |
| WO-2002023185-A2 | DEVICES AND METHODS FOR DIRECT ELECTRONIC READOUT OF BIOMOLECULAR INTERACTIONS | ENGENEOS, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-5958682-A | VIRUS-DIRECTED ENZYME PRODRUG THERAPY FOR TREATING TUMOR CELLS CONSISTING OF A VIRAL VECTOR ENCODING BACTERIAL NITROREDUCTASE CAPABLE OF CONVERTING A PRODRUG INTO A CYTOTOXIC DRUG OPERABLY LINKED TO A PROMOTER; AND THE PRODRUG | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-09-28 | — | — | US | claimed |
| WO-1994021118-A1 | GENE-THERAPY COMPOSITION AND METHOD FOR TREATING CARCINOMAS | THE UAB RESEARCH FOUNDATION (US) | 1994-09-29 | — | — | WO | claimed |
| EP-0429454-A1 | IMPROVEMENTS RELATING TO THE CONTROL OF NEOPLASTIC TISSUE GROWTH | Roberts, John J. (GB) | 1991-06-05 | — | — | EP | claimed |
| EP-0330432-A1 | Improvements relating to the control of neoplastic tissue growth | Roberts, John J. (GB) | 1989-08-30 | — | — | EP | claimed |
| WO-1989007592-A1 | IMPROVEMENTS RELATING TO THE CONTROL OF NEOPLASTIC TISSUE GROWTH | ROBERTS JOHN J (GB) | 1989-08-24 | — | — | WO | claimed |